Exelixis Company Profile (NASDAQ:EXEL)

Analyst Ratings

Consensus Ratings for Exelixis (NASDAQ:EXEL) (?)
Ratings Breakdown: 4 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $9.00 (4.17% upside)

Analysts' Ratings History for Exelixis (NASDAQ:EXEL)
Show:
DateFirmActionRatingPrice TargetActions
7/19/2016Leerink SwannReiterated RatingBuy$10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/7/2016Cowen and CompanyReiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/26/2016Stifel NicolausBoost Price TargetBuy$7.00 -> $8.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/13/2016William BlairReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/20/2015Piper Jaffray Cos.Reiterated RatingHold$2.50 -> $6.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/26/2014 forward)

Earnings

Earnings History for Exelixis (NASDAQ:EXEL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/3/2016ListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/4/2016Q116($0.25)($0.27)$9.11 million$15.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/29/2016Q415($0.22)($0.19)$8.16 million$9.94 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2015Q315($0.20)($0.22)$9.08 million$9.85 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2015Q215($0.21)($0.22)$8.69 million$8.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/30/2015Q115($0.24)($0.18)$8.08 million$9.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/24/2015Q414($0.31)($0.30)$7.50 million$7.35 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/4/2014Q314($0.37)($0.32)$6.77 million$6.30 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/31/2014Q214($0.39)($0.38)$5.66 million$6.56 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/1/2014Q114($0.37)($0.39)$6.11 million$4.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/20/2014Q413($0.38)($0.38)$5.71 million$4.34 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/30/2013Q313($0.37)($0.36)$5.55 million$5.50 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2013Q2 2013($0.30)($0.34)$6.55 million$11.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2013Q1 2013($0.29)($0.24)$5.33 million$9.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/21/2013Q4 2012($0.24)($0.28)$9.46 million$7.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2012Q312($0.30)($0.20)$9.22 million$13.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/2/2012($0.27)($0.25)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/3/2012($0.19)($0.18)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/27/2011$0.57$0.60ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/4/2011($0.17)($0.16)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/3/2011($0.19)($0.24)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/22/2011($0.21)($0.16)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Exelixis (NASDAQ:EXEL)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.27)($0.24)($0.26)
Q2 20162($0.29)($0.28)($0.29)
Q3 20162($0.26)($0.25)($0.26)
Q4 20162($0.22)($0.19)($0.21)
Q1 20171($0.16)($0.16)($0.16)
Q2 20171($0.17)($0.17)($0.17)
Q3 20171($0.14)($0.14)($0.14)
Q4 20171($0.11)($0.11)($0.11)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Exelixis (NASDAQ:EXEL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Exelixis (NASDAQ:EXEL)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/11/2016Lance WillseyDirectorBuy60,000$4.97$298,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/9/2016Lance WillseyDirectorBuy40,000$4.97$198,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/11/2015Lance WillseyDirectorBuy100,000$4.89$489,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/16/2015Peter LambEVPSell51,549$5.80$298,984.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/13/2015Peter LambEVPSell600$5.80$3,480.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/12/2015Peter LambEVPSell300,276$5.84$1,753,611.84View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/17/2014Vincent T MarchesiDirectorBuy20,000$1.71$34,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/29/2013Lance WillseyDirectorBuy10,000$5.15$51,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/20/2012Vincent T MarchesiDirectorBuy4,000$4.68$18,720.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/19/2012Vincent T MarchesiDirectorBuy6,000$4.72$28,320.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/10/2012Gisela SchwabEVPBuy25,000$4.39$109,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Exelixis (NASDAQ:EXEL)
DateHeadline
07/26/16 10:04 PMRecent Analysts Ratings of Stocks: Exelixis, (NASDAQ:EXEL) , Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) - Street Updates
07/26/16 05:52 AMHave a look at Analyst Actions: Exelixis, Inc. (NASDAQ:EXEL) , Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Street Updates
07/26/16 05:52 AMWhich way Exelixis, Inc. (NASDAQ:EXEL) insiders are heading ... - Review Fortune
07/25/16 03:58 PMIpsen and its Partner Exelixis Receive Positive CHMP Opinion for...
07/25/16 08:37 AMD-Day For TBRA, Nicox Falls As FDA Rejects Vesneo, EXEL Awaits EMA Decision
07/24/16 08:28 AMIs $10 Price Target Attainable For Exelixis, Inc. (NASDAQ:EXEL)? - Investor Newswire
07/23/16 02:36 PMCancer Stocks: 2 to Buy, 1 to Avoid - Here's why you may want to add Bellicum Pharmaceuticals and Exelixis to your portfolio but avoid Ariad Pharmaceuticals.
07/23/16 08:00 AMNews review of 2 biotech stocks: Exelixis, Inc. (NASDAQ:EXEL), Gilead Sciences Inc. (NASDAQ:GILD) - The Voice Registrar
07/23/16 08:00 AMAnalyst's Overview of Two Stocks: Exelixis, Inc. (NASDAQ:EXEL) , Wright Medical Group N.V. (NASDAQ:WMGI) - Street Updates
07/23/16 08:00 AMIdentifying Analyst Ratings Summary To Consider: Kennametal Inc. (NYSE:KMT), Exelixis, Inc. (NASDAQ:EXEL) - Review Fortune
07/23/16 08:00 AMExelixis Inc. (EXEL) Hits New 52-week High During July 21 Session - Equities.com
07/23/16 08:00 AMExelixis Inc versus Five Prime Therapeutics Inc Head to Head Compare - CML News
07/22/16 03:51 PMBRIEF-EU Medicines Agency recommends approval of two new cancer drugs
07/22/16 03:51 PMExelixis (EXEL) and Ipsen Announces Positive CHMP Opinion for Cabometyx to Treat Advanced RCC
07/22/16 03:51 PMIpsen and its Partner Exelixis Receive Positive CHMP …
07/22/16 03:51 PMCommit To Buy Exelixis At $5, Earn 12% Using Options
07/22/16 03:51 PMIpsen and its Partner Exelixis Receive Positive CHMP Opinion for Cabometyx ...
07/22/16 10:18 AMIpsen and its Partner Exelixis Receive Positive CHMP Opinion for Cabometyx™ (Cabozantinib) for the Treatment of Advanced RCC in Adults Following Prior VEGF-Targeted Therapy - [at noodls] - CHMP recommends approval of Cabometyx™ (cabozantinib) for the treatment of advanced renal cell carcinoma (RCC) in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy based ...
07/22/16 05:40 AMExelixis Inc. (EXEL) Hits New 52-week High During July 20 Session - Equities.com
07/21/16 09:26 PMExelixis, Inc. (NASDAQ:EXEL): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/21/16 09:26 PMBiotech Bulls n Bears: Exelixis, Inc. (NASDAQ:EXEL), Ligand Pharmaceuticals Incorporated (NASDAQ:LGND ... - KC Register
07/21/16 04:05 PMBiogen’s CEO Is Out After Management Changes, Stalled Sales (2)
07/21/16 01:46 PMExit of Biogen CEO George Scangos could be big for Bay Area biotechs - George Scangos, the CEO of Biogen Inc. for the past six years, will step down from his post to return to the West Coast and spend time with his family. The news is big for Biogen (NASDAQ: BIIB), which Scangos led through a turnaround from South San Francisco's Exelixis Inc. (NASDAQ: EXEL), but it may be even bigger for Bay Area biotech companies. Any biotech searching for a well-respected CEO with a solid track record is sure to call on Scangos. Scangos lives in the Bay Area half time. Biogen…
07/21/16 07:29 AMLeerink Reiterates Positive Stance on Exelixis, Inc. (EXEL) Heading Into 2Q Earnings - Smarter Analyst
07/21/16 07:29 AMTime To Put On The Watch List? - Novavax, Inc. (NASDAQ:NVAX), Exelixis, Inc. (NASDAQ:EXEL) - The Voice Registrar
07/21/16 07:28 AMWhat Will Happen to Exelixis, Inc. Next? The Stock Just Reaches 52-Week High - Consumer Eagle
07/21/16 07:28 AMAnalysts Tips to Monitor: Boston Scientific Corporation (NYSE:BSX) , Exelixis, Inc. (NASDAQ:EXEL) - Street Updates
07/21/16 07:28 AMHC Stocks Judgment: Eli Lilly and Co (NYSE:LLY), Exelixis, Inc. (NASDAQ:EXEL) - share market updates (press release)
07/20/16 05:37 AMShares Positive Over the Past Month: Exelixis, Inc. (NASDAQ:EXEL) - TGP
07/19/16 09:12 PMExelixis, Inc. (NASDAQ:EXEL) Declined -0.24%: Galena Biopharma Inc (NASDAQ:GALE), ServiceNow, Inc. (NYSE ... - KC Register
07/19/16 09:12 PMEquity Roundup: Stock Performance Focus on Exelixis, Inc. (NASDAQ:EXEL) - Press Telegraph
07/19/16 09:12 PMHC Stocks Momentum: Express Scripts Holding Company (NASDAQ:ESRX), Exelixis, Inc. (NASDAQ:EXEL) - share market updates (press release)
07/19/16 09:12 PMNoteworthy Analyst's Rating to Observe: Exelixis, Inc. (NASDAQ:EXEL) , Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) - Street Updates
07/18/16 04:04 PMEXEL Crosses Above Average Analyst Target
07/18/16 09:05 AMWill Exelixis, Inc. (NASDAQ:EXEL) Surprise Analysts? - Investor Newswire
07/18/16 09:05 AMPhilip Morris International Inc. (NYSE:PM) & Exelixis, Inc. (NASDAQ:EXEL) Stocks Buzz - Money News (press release)
07/18/16 09:05 AMAnalyst Recommendations Review: Exelixis, Inc. (NASDAQ:EXEL) - News Oracle
07/16/16 07:21 AMAnalyst Overview: Exelixis, Inc. (NASDAQ:EXEL) - News Oracle
07/15/16 05:49 AMSummary of Analyst's Study: Exelixis, Inc. (NASDAQ:EXEL) , Brookdale Senior Living Inc. (NYSE:BKD) - Street Updates
07/14/16 09:17 PMExelixis, Inc. (NASDAQ:EXEL) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/14/16 04:03 PMStocks Trending Alert: Baker Hughes Incorporated (BHI), Exelixis, Inc. (EXEL), The Charles Schwab Corporation (SCHW) - iStreetWire
07/14/16 04:03 PMExelixis Inc Realized Volatility Hits Elevated Level - CML News
07/14/16 07:13 AMAnalyst Target and Average Rating Watch: Exelixis, Inc. (NASDAQ:EXEL) - Press Telegraph
07/14/16 07:13 AMExelixis, Inc. (NASDAQ:EXEL) Current Analyst Ratings - Fiscal Standard
07/14/16 07:13 AMHC Stocks Highlights: Exelixis, Inc. (NASDAQ:EXEL), Endo International plc (NASDAQ:ENDP) - share market updates (press release)
07/14/16 07:13 AMHalcon Resources (NYSE:HK) & Exelixis, Inc. (NASDAQ:EXEL) Stocks Intraday Alert - Money News (press release)
07/12/16 04:05 PMPrice Target Update: Exelixis, Inc. (NASDAQ:EXEL) - News Oracle
07/12/16 04:05 PMExelixis Inc.: Exelixis to Release Second Quarter 2016 Financial Results on Wednesday, August 3, 2016 - The Wall Street Transcript
07/12/16 03:33 PMExelixis to Release Second Quarter 2016 Financial Results on Wednesday, August 3, 2016 - [at noodls] - - Conference Call and Webcast to Follow at 5:00 p.m. EDT/ 2:00 p.m. PDT - SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jul. 12, 2016-- Exelixis, Inc. (NASDAQ: EXEL) announced today that its second quarter ...
07/11/16 03:57 PMStock Climbing to a Recent High: Exelixis, Inc. (NASDAQ:EXEL) - Press Telegraph

Social

About Exelixis

Exelixis logoExelixis, Inc. is a biopharmaceutical company. The Company is engaged in developing small molecule therapies for the treatment of cancer. It focuses on the development and commercialization of cabozantinib, an inhibitor of multiple receptor tyrosine kinases, in various tumor indications. Cabozantinib is indicated for the treatment of progressive, metastatic medullary thyroid cancer, and is sold under the brand name COMETRIQ. It is evaluating Cabozantinib in a development program, which consists of over 45 clinical trials, across multiple indications, including pivotal studies in advanced renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). Its other products are Cobimetinib and XL888. Cobimetinib is a potent, selective inhibitor of MEK, a kinase that is a component of the RAS/RAF/MEK/ERK pathway. XL888 is a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90), a molecular chaperone protein that affects the activity and stability of a range of regulatory proteins.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: EXEL
  • CUSIP: 30161Q10
Key Metrics:
  • Previous Close: $8.64
  • 50 Day Moving Average: $7.93
  • 200 Day Moving Average: $5.42
  • P/E Ratio: N/A
  • P/E Growth: 0.37
  • Market Cap: $1.98B
  • Beta: 2.1
  • Current Year EPS Consensus Estimate: $-0.97 EPS
  • Next Year EPS Consensus Estimate: $-0.48 EPS
Additional Links:
Exelixis (NASDAQ:EXEL) Chart for Tuesday, July, 26, 2016